1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Indivior Acquires Opiant Pharmaceuticals

M&A Deal Summary

Indivior Acquires Opiant Pharmaceuticals

On November 14, 2022, Indivior acquired life science company Opiant Pharmaceuticals for 145M USD

Acquisition Highlights
  • This is Indivior’s 1st transaction in the Life Science sector.
  • This is Indivior’s largest (disclosed) transaction.
  • This is Indivior’s 1st transaction in the United States.
  • This is Indivior’s 1st transaction in California.

M&A Deal Summary
Date 2022-11-14
Target Opiant Pharmaceuticals
Sector Life Science
Buyer(s) Indivior
Deal Type Add-on Acquisition
Deal Value 145M USD
Advisor(s) Lazard (Financial)
Latham & Watkins (Legal)

Target

Opiant Pharmaceuticals

Santa Monica, California, United States
Opiant Pharmaceuticals is a biopharmaceutical company developing treatments for addiction and drug overdose leveraging intranasal and injectable delivery technologies. Opiant Pharmaceuticals was founded in 2005 and is based in Santa Monica, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Indivior

North Chesterfield, Virginia, United States
Category Company
Founded 2014
Sector Life Science
Employees1,030
Revenue 1.2B USD (2024)
DESCRIPTION

Indivior is a global pharmaceutical company specializing in developing and commercializing treatments for substance use disorders and serious mental health conditions. It offers a portfolio of buprenorphine-based therapies for opioid use disorder. Indivior was founded in 2014 and is based in North Chesterfield, Virginia.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2022 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal